This should be good for Elite and anyone else entering the marketplace. Priority review will fast-track Elite's ART products. Only a handful of companies will be in this billion dollar marketplace over the next decade. In my opinion Elite will be bought out during this period - likely early on - but Elite's technology/delivery system will garner the lion share of the ART market for whoever purchases Elite and furthermore this tech will be considered best practice in patient care and widely adopted throughout the healthcare system (assuming the prices are competitive due cost containment, which they should be).
News 
Market Data 
Discover 
AI
